JMP Securities downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades Hot Downgrades

RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60 March 16, 2016 9:46 AM Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from TakedaMarch 16, 2016 7:56 AM Orexigen Therapeutics (OREX) Files $150M Mixed ShelfMarch 15, 2016 5:26 PM Form S-3 Orexigen Therapeutics, March 15, 2016 5:25 PM Orexigen Therapeutics (OREX) Enters Mysimba Commercialization Agreement with Valeant (VRX)March 15, 2016 7:03 AM Orexigen (OREX), Takeda to Terminate CONTRAVE Amended, Restated Collaboration AgreementMarch 15, 2016 7:01 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and EasternMarch 15, 2016 7:00 AM Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicineMarch 15, 2016 7:00 AM Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United StatesMarch 15, 2016 7:00 AM